Regeneron will spend up to $490 million on manufacturing, labs this year

Regeneron Pharmaceuticals could increase its capital expenditures by more than $100 million this year. The manufacturer of bulk medications for treating skin cancer, eye disease and asthma plans to invest up to $490 million on renovations and expansion of its factories in East Greenbush, New York, and Limerick, Ireland. Investments also will include laboratory improvements at Regeneron's Tarrytown location, where the company is headquartered. Regeneron (NASDAQ: REGN) spent $383.1 million on capital…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news